Obesity and kidney cancer

A large review of the data showed that cancer specific survival and prognosis were improved in renal cell carcinoma (RCC) patients who were overweight or obese compared with patients with a normal body mass index (BMI). Data from 50,717 RCC patients were reviewed in this study. This review showed that cancer specific survival, progression-free survival […]

read more

Active surveillance for young patients with small renal masses

Active surveillance is increasingly being used for the management of small renal masses. However, questions remain regarding the safety and durability of active surveillance in younger patients. Two hundred and twenty four (224) patients aged 60 or younger were included in the study and followed for an average of 4.9 years. 30.4% of these patients […]

read more

Psychosocial effects of kidney cancer

As with most cancers, the psychosocial effects of renal cell carcinoma (RCC) are profound. Around 20% of patients experience depression and 30% experience anxiety due to various reasons, such as treatment side effects, disease-related changes, finances and coping strategies. Not only are these symptoms distressing, they can also affect survival. This was described using two […]

read more

The significance of body mass index (BMI) on kidney cancer outcomes

Being overweight or obese is a well-known risk factor for kidney cancer. This study, published in the Journal of Urology, looked at how body mass index (BMI) affects the survival of a total of 50,717 kidney cancer patients. Overweight and obese patients were associated with improved survival compared to patients with normal BMI, while underweight […]

read more

Blood tumour biomarker for kidney cancer survival

Researchers are constantly looking for biomarkers to help predict which patients will respond to each kidney cancer treatment. A study in Scandinavia has discovered a protein called tumour associated trypsin inhibitor (TATI) that is a biomarker for several tumours and for inflammation. High levels of TATI in the blood predicts an unfavourable outcome for many […]

read more

Inflammatory biomarkers for non-metastatic kidney cancer

This study looked at inflammatory biomarkers in the blood for the diagnosis of non-metastatic renal cell carcinoma (RCC).  Inflammation is known to be associated with cancer, and there have been a number of studies that have looked at the relationship between cancer and inflammatory biomarkers. Inflammatory biomarkers such as the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte […]

read more

Impact of lymph-node positive kidney cancer on survival

A recent study published in the journal Cancer last month compared the survival of 8,988 kidney cancer patients from the American National Cancer Data Base to assess the impact of cancer spread to the lymph nodes in patients with stage III renal cell carcinoma (RCC). The researchers found that the 5-year survival rate of patients […]

read more

Effect of obesity and being overweight on complications and survival after surgery in kidney cancer patients

A recent study published in the Journal of Endourology this month shows that obese and overweight patients do not experience higher complication rates or worse kidney function after key-hole (laparoscopic) surgery for stage 2 kidney cancer. This surgery can, therefore, be deemed feasible and safe in this group of patients. Nevertheless, obese and overweight patients […]

read more

Renal function after surgery for kidney cancer may impact cancer-specific survival

The results from a single-centre study reported in Clinical Genitourinary Cancer recently found that partial nephrectomy (nephron-sparing surgery) for localised renal cell carcinoma (RCC) may decrease the risk of cancer-specific mortality in some patients. The study was conducted in 1767 patients who underwent either partial or radical nephrectomy for RCC at the University of Brescia […]

read more

C-reactive protein as a potential predictive biomarker for kidney cancer

A recent study published in Science Direct describes how a change in blood C-reactive protein (CRP) levels during the early phase of nivolumab treatment for metastatic renal cell carcinoma (mRCC) may be used to predict survival among patients with mRCC. Read more in Science Direct here

read more
Showing 1 to 10 of 67 results
  TOP